Using the Symmetry Analysis Design to Screen for Adverse Effects of Non-vitamin K Antagonist Oral Anticoagulants.

Author: HallasJesper, HellfritzschMaja, PottegårdAnton, RasmussenLotte

Paper Details 
Original Abstract of the Article :
INTRODUCTION: Knowledge on adverse effects (AEs) related to non-vitamin K antagonist oral anticoagulants (NOACs) in real-world populations is sparse. OBJECTIVE: Our objective was to identify signals of potential AEs in patients with atrial fibrillation (AF) initiating NOAC treatment using a hypothe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s40264-018-0650-6

データ提供:米国国立医学図書館(NLM)

Unveiling the Side Effects of Non-Vitamin K Antagonist Oral Anticoagulants

The study explores the [adverse effects (AEs)] associated with [non-vitamin K antagonist oral anticoagulants (NOACs)] in a [real-world] setting. The authors used a [hypothesis-free screening approach] to identify potential [AEs] in patients with [atrial fibrillation (AF)] who were initiated on [NOAC] treatment. Their research aimed to provide valuable insights into the [safety profile] of these widely used [anticoagulants].

Identifying Adverse Effects of NOACs in Atrial Fibrillation

The study found a [number of potential AEs] associated with [NOAC] therapy in [patients] with [atrial fibrillation (AF)]. The researchers identified [signals] of [potential AEs] in various categories, including [bleeding], [gastrointestinal symptoms], [mental disease], [urinary tract disorders], and [musculoskeletal symptoms].

Navigating Anticoagulation Therapy: A Balancing Act

The study highlights the importance of being aware of the [potential side effects] associated with [NOACs]. It emphasizes the need for careful [monitoring] and [risk management] to ensure [safe and effective] treatment. Remember, [anticoagulation therapy] is often essential for preventing [stroke] in patients with [atrial fibrillation (AF)], but it is crucial to weigh the [potential benefits] against the [potential risks].

Dr. Camel's Conclusion

The study offers a [comprehensive] overview of the [potential AEs] associated with [NOACs]. The researchers have successfully used a [novel] approach to identify [signals] that warrant further investigation. As we navigate the [desert] of [pharmacovigilance], we must remain vigilant in monitoring the [safety] of [new medications] and ensuring that they are used appropriately.

Date :
  1. Date Completed 2018-11-06
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

29498009

DOI: Digital Object Identifier

10.1007/s40264-018-0650-6

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.